Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 3/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CTSA | P10619 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129808 | 0.89 | AVPR2 (0.49) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL15226766 | 0.84 | CNR2 (0.48) | LMNAPOLBCNR2MAPTCTSA | |
| SCHEMBL12274686 | 0.84 | CTSA (0.50) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL10216923 | 0.84 | LMNA (0.46) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL19265317 | 0.84 | LMNA (0.46) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL27924870 | 0.84 | CTSA (0.50) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL10216855 | 0.84 | LMNA (0.48) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL10130112 | 0.82 | CTSS (0.49) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL10216766 | 0.80 | LMNA (0.47) | AVPR2AVPR1ALMNAPOLBCNR2 | |
| SCHEMBL10217086 | 0.80 | LMNA (0.47) | AVPR2AVPR1ALMNAPOLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616448-B1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034855-B2 | Substituted phenylacetate and phenylpropane amides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| WO-2012035075-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231313-A1 | SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF | AADAC, NAT1, DNPEP | AVPR2 905/4885AVPR1A 751/4885LMNA 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.